E

    Enveric Biosciences Inc (ENVB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.37
    +0.00 (+0.00%)

    Market Cap: $6.13M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    56%(14/25)
    Avg Surprise
    -463.70%
    PeriodReportedEst.SurpriseB/MYoY
    Jun 26
    		$-0.76N/AN/ABeat+93.5%
    Mar 26
    		$-1.08N/AN/ABeat+77.5%
    Dec 25
    		$-3.81N/AN/ABeat-87.5%
    Sep 25
    		$-10.81$-0.35-2988.57%Miss+75.0%
    Jun 25
    		$-11.65$-0.35-3228.57%Miss+74.1%
    Mar 25
    		$-4.82$-0.40-1104.20%Miss+95.6%
    Dec 24
    		$-2.03$-2.76+26.45%Beat-38.1%
    Sep 24
    		$-43.20N/A+53.85%Beat+85.0%
    Jun 24
    		$-45.00N/A+54.55%Beat+90.0%
    Mar 24
    		$-109.80$-139.50+21.29%Beat-2492.7%
    Dec 23
    		$-1.47$-1.54+4.55%Beat+99.6%
    Sep 23
    		$-287.12$-376.20+23.68%Beat+50.7%
    Jun 23
    		$-450.42$-117.00-284.97%Miss+44.9%
    Mar 23
    		$-4.24$-2.23-89.91%Miss+99.6%
    Dec 22
    		$-344.11$-525.60+34.53%Beat-286.6%
    Sep 22
    		$-582.21$-720.00+19.14%Beat+46.1%
    Jun 22
    		$-818.08$-675.00-21.20%Miss+54.6%
    Mar 22
    		$-990.00$-1080.00+8.33%Beat-2474900.0%
    Dec 21
    		$-89.00$-8.00-1012.50%Miss-222400.0%
    Sep 21
    		$-1080.00$-1260.00+14.29%Beat-224900.0%
    Jun 21
    		$-1800.00$-1575.00-14.29%Miss-4499900.0%
    Mar 21
    		$-0.04N/A+99.58%Beat-60.0%
    Sep 20
    		$-0.04N/AN/ABeat+94.7%
    Jun 20
    		$-0.48N/AN/ABeat+52.0%
    Mar 20
    		$-0.04N/AN/ABeat+100.0%
    Sep 19
    		$-0.03N/A+99.50%Beat+100.0%
    Jun 19
    		$-0.75N/A+99.50%Beat+99.8%
    Mar 19
    		$-1.00N/AN/ABeat+55.6%
    Dec 18
    		$-1600.00$-200.00-700.00%Miss-28990.9%
    Sep 18
    		$-300.00$-250.00-20.00%Miss-115284.6%
    Jun 18
    		$-300.00$-400.00+25.00%Beat-333233.3%
    Mar 18
    		$-2.25$-0.08-2712.50%Miss-124.0%
    Sep 17
    		$-5.50N/AN/ABeat+56.3%
    Jun 17
    		$-0.26N/AN/ABeat-
    Mar 17
    		$-0.09N/AN/ABeat-
    Dec 16
    		$9.37N/AN/ABeat-
    Sep 16
    		$-12.59N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-0.08EV/EBITDA0.29x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-170.00%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage-8571.36x
    Current Ratio10.21xQuick Ratio10.21x
    Trading Statistics
    Beta1.11Avg Volume139.85K
    52-Week High$13.6352-Week Low$1.17

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.38
    SMA 20$1.47
    SMA 50$1.42
    SMA 200$2.82
    EMA 10$1.40
    EMA 20$1.43
    EMA 50$1.54
    EMA 200$3.84

    MACD

    Line: -0.03Signal: -0.02Hist: -0.01

    ADX

    ADX: 18.2+DI: 15.2-DI: 25.4

    Aroon & PSAR

    Aroon Up24.0
    Aroon Down88.0
    PSAR$1.50

    Bollinger Bands

    Upper Band$1.69
    Lower Band$1.26
    %B Position2908%(Upper)
    Band Width0.26

    RSI (14-Day)

    Neutral
    43.3

    Momentum Oscillators

    Stoch %K44.4
    Stoch %D44.4
    Williams %R-55.6
    ROC (10d)-7.4%
    Momentum-0.11
    CCI (20d)-84.7
    MFI (14d)24.1

    Volatility Measures

    ATR (14d)$0.12(8.9%)
    StdDev (20d)0.11
    Hist Vol60.3%(High)

    Volume Flow

    VWAP$1.36
    OBV259.8M
    AD Line13.4B
    CMF (20d)-0.015

    Volume Metrics

    Avg Vol (20d)142.6K
    Vol Ratio0.3x(Low)
    VWMA (20d)$1.46

    Pivot Points

    R3$1.48
    R2$1.44
    R1$1.41
    Pivot Point$1.37
    S1$1.34
    S2$1.30
    S3$1.27

    Advanced Oscillators

    TSI-8.97
    Ultimate Osc55.0
    KST-14.38

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total RevenueN/A$0$0$0$0$0$340,376$0$0$0$647,092$0
    Cost of Revenue$36,826$37,240$39,485$40,369$39,980$81,024$82,487$84,814$84,779$85,409$84,682$95,839
    Gross Profit$-36,826$-37,240$-39,485$-40,369$-39,980$-81,024$-82,487$-84,814$-84,779$-85,409$-84,682$-95,839
    Operating Expenses$2.99M$1.60M$2.15M$1.83M$2.48M$2.11M$3.09M$2.00M$1.81M$2.39M$2.30M$3.35M
    R&D$1.36M$345,969$372,178$402,417$1.26M$746,371$1.10M$762,717$515,501$458,155$1.37M$1.35M
    SG&A$1.64M$1.25M$1.78M$1.43M$1.22M$1.36M$1.99M$1.24M$1.30M$1.93M$2.78M$2.01M
    Operating Income$-3,027,441$-1,633,170$-2,193,923$-1,873,943$-2,519,049$-2,187,533$-3,173,826$-2,083,192$-1,897,931$-2,477,320$-2,384,360$-3,448,395
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$292$303$250$274$132$0$0$217$35$696$544$2,237
    Income Before Tax$-3,027,733$-1,633,473$-2,194,171$-1,873,669$-2,519,181$-2,184,966$-3,147,447$-2,084,032$-1,879,394$-2,455,184$-3,413,618$-2,815,621
    Income Tax Expense$0$0$0$1.51M$0$0$7,199$0$1$1,731$22,318$6,595
    Net Income$-3,027,733$-1,633,473$-2,194,171$-1,873,669$-2,519,181$-2,184,966$-3,154,646$-2,084,032$-1,879,394$-2,456,915$-3,435,936$-2,822,216
    EBITDA$-2,990,615$-1,595,930$-2,154,436$-1,833,300$-2,479,199$-2,103,947$-3,064,960$-1,999,221$-1,794,610$-2,369,775$-3,328,936$-2,719,782
    EBIT$-3,027,441$-1,633,170$-2,193,921$-1,873,669$-2,519,179$-2,184,971$-3,147,447$-2,084,035$-1,879,389$-2,455,184$-3,413,618$-2,815,621
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ENVB

    News

    ARMISTICE CAPITAL, LLC Acquires Stake in Enveric Biosciences Inc (ENVB)

    ARMISTICE CAPITAL, LLC has acquired 405,092 shares of Enveric Biosciences Inc (ENVB), representing a 9.99% stake in the company. This move by the healthcare-focused investment firm signals a speculative bet on Enveric's neuroplastogenic drug pipeline, despite the biotechnology company's significant operational challenges and poor financial metrics. Enveric Biosciences specializes in developing therapeutics for mental health disorders, but faces issues such as negative returns on equity and assets, and zero revenue growth.

    GuruFocus•8/21/26•
    Somewhat-Bearish

    Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026

    Enveric Biosciences reported its financial results and provided a corporate update for the second quarter ended June 30, 2026. The company highlighted significant progress in the development of its lead candidate, EB-003, a non-hallucinogenic neuroplastogen, including advancement of IND-enabling studies and promising preclinical data. Enveric also expanded its intellectual property portfolio and secured approximately $6.5 million in funding through a private placement and warrant exercises.

    BioSpace•8/17/26•
    Bullish

    Enveric Biosciences (ENVB) posts H1 2026 loss but raises $8.3M cash

    Enveric Biosciences reported a net loss of $4,661,206 for the first half of 2026 and an accumulated deficit of $119,507,698, with no revenue. Despite these losses, the company raised $8,348,207 in net financing cash inflows, boosting its cash balance to $8,296,296. Management expressed substantial doubt about the company's ability to continue as a going concern without additional capital, and internal controls over financial reporting remain ineffective.

    Stock Titan•8/15/26•
    Bearish

    Enveric Biosciences reports $3.0M net loss, $8.3M cash on hand for Q2 2026

    Enveric Biosciences reported a net loss of $3.0 million for Q2 2026 and $8.3 million in cash on hand. The company raised approximately $6.5 million through a private placement and warrant exercises. Significant progress was noted in IND-enabling studies for its lead candidate EB-003 and the expansion of its intellectual property portfolio.

    TradingView•8/14/26•
    Neutral

    Enveric Biosciences Posts $3.0 Million Second-Quarter Net Loss

    Enveric Biosciences (ENVB) reported a net loss of $3.0 million for the second quarter ended June 30, 2026, compared to a $2.5 million net loss in the prior-year quarter. The biotechnology company finished the quarter with $8.3 million in cash, advanced its EB-003 development, and secured new patent allowances. Additionally, institutional investors showed increased activity in ENVB stock, with several hedge funds adding shares to their portfolios.

    Quiver Quantitative•8/14/26•
    Somewhat-Bearish

    Frequently Asked Questions About ENVB

    Does ENVB pay dividends?
    Enveric Biosciences Inc (ENVB) does not currently pay a regular dividend.
    What is ENVB's market cap?
    Enveric Biosciences Inc (ENVB) has a market capitalization of $6.13M with a current stock price of $1.37.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In